查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1720730

2025年全球乳癌液态切片市场报告

Breast Cancer Liquid Biopsy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年乳癌液态切片的市场规模将快速成长。到 2029 年，这一数字将成长至 15.6 亿美元，复合年增长率为 14.7%。预测期内的成长动力包括液态切片检测技术的进步、液态切片在早期癌症筛检中的应用不断增加、即时癌症监测的需求不断增长、精准肿瘤学应用的扩大以及液态切片研发投资的增加。主要趋势包括人工智慧在液态切片分析中的整合、单细胞测序的进展、多体学液态切片平台的开发、提高液态切片的敏感性和特异性，以及采用数位 PCR 进行超精确突变检测。

预计未来几年乳癌病例数的增加将推动乳癌液态切片市场的成长。乳癌是一种始于乳腺细胞的恶性肿瘤，通常发生在乳腺小叶或将乳汁输送到乳头的导管中。乳癌发生率的上升是由于遗传倾向、荷尔蒙失调、老化、生活方式改变、肥胖、饮酒、缺乏运动、辐射暴露和环境污染等因素造成的。乳癌液态切片透过检测血液中的循环肿瘤DNA（ctDNA）或循环性肿瘤细胞（CTC）并实现即时病情监测，在治疗中发挥重要作用。它有助于评估治疗效果、检测抗治疗性并识别基因突变以进行标靶治疗。例如，根据致力于癌症研究、教育、宣传和患者支持的美国非营利组织美国癌症协会的数据，预计乳癌新患者数将从 2024 年的 313,510 例增加到 2025 年的 319,750 例。因此，乳癌发生率的上升刺激了乳癌液态切片市场的扩张。

乳癌液态切片市场的主要企业正专注于伴同性诊断等市场创新，透过识别最能从特定治疗方法中受益的患者来促进个人化护理。伴同性诊断利用液态切片技术检测指示治疗反应的生物标记物，例如基因突变、循环肿瘤DNA（ctDNA）和蛋白质表现。例如，2023年1月，美国生物技术公司Guardant Health Inc.的食品药物管理局 CDx液态切片测试获得美国食品药物管理局（FDA）核准，作为美纳里尼集团ORSERDU（elacestrant）的伴同性诊断，用于治疗患有ESR1基因突变的进行性或转移性乳癌患者。获得此项核准后，肿瘤学家现在可以使用该测试进行全面的基因组分析，以识别可能受益于标靶治疗的患者。这也标誌着 Guardant Health 首次获得 FDA核准用于治疗乳癌，扩大了该公司在精准肿瘤学领域的影响力。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 - 市场 - 宏观经济情境 宏观经济情境包括利率、通膨、地缘政治以及感染疾病和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球乳癌液态切片PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球乳癌液态切片市场：成长率分析
  • 全球乳癌液态切片市场表现：规模与成长，2019-2024
  • 全球乳癌液态切片市场预测：规模与成长，2024-2029 年，2034 年
  • 全球乳癌液态切片总目标市场（TAM）

第六章市场区隔

  • 全球乳癌液态切片市场：依产品、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 耗材
  • 套件
  • 全球乳癌液态切片市场（依生物标记、绩效及预测）：2019-2024 年、2024-2029 年、2034 年
  • 细胞外囊泡（EVs）
  • 游离DNA（cfDNA）
  • 循环肿瘤RNA（ctRNA）
  • 循环性肿瘤细胞（CTC）
  • 游离RNA（cfRNA）
  • 其他生物标誌物
  • 全球乳癌液态切片市场应用、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 早期检测或筛检
  • 诊断
  • 其他用途
  • 全球乳癌液态切片市场（按最终用户、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 研究所
  • 医院
  • 医生检查室
  • 参考实验室
  • 公共卫生研究所
  • 研究组织
  • 小分子研究所
  • 病理学研究所
  • 全球乳癌液态切片市场按耗材类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 试剂
  • 聚合酵素链锁反应（PCR）检测
  • 定序面板
  • 样本采集管
  • 全球乳癌液态切片市场细分（按套件类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • DNA液态生物检体套件
  • 基于RNA的液态生物检体套件
  • 多标记液态生物检体套件

第七章 区域和国家分析

  • 全球乳癌液态切片市场：按地区、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 全球乳癌液态切片市场：依国家/地区、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

  • 乳癌液态切片市场：竞争格局
  • 乳癌液态切片市场：公司简介
    • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
    • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

  • Agilent Technologies Inc.
  • Illumina Inc.
  • Sysmex Corporation
  • Qiagen NV
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories
  • Guardant Health Inc.
  • Twist Bioscience
  • Foundation Medicine Inc.
  • Biodesix Inc.
  • Menarini Silicon Biosystems
  • Datar Cancer Genetics
  • Abcam plc
  • OncoDNA SA
  • Genomic Health Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

  • 2029年乳癌液态切片市场：哪些国家将带来新机会
  • 2029年乳癌液态切片市场：细分领域带来新机会
  • 2029年乳癌液态切片市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第36章 附录

简介目录
Product Code: r33985

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient's blood or other bodily fluids, offering valuable insights into the presence, progression, and genetic profile of breast cancer without the need for a traditional tissue biopsy.

The primary products used in breast cancer liquid biopsy include consumables and kits. Consumables refer to disposable materials, reagents, and kits utilized in liquid biopsy tests to detect and analyze biomarkers associated with breast cancer. The key biomarkers include extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), cell-free RNA (cfRNA), and others. These biomarkers are applied in early detection or screening, diagnosis, and other purposes. The end users of breast cancer liquid biopsy encompass laboratories, hospitals, physician laboratories, reference laboratories, public health laboratories, research institutes, small molecular laboratories, and pathology laboratories.

The breast cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides breast cancer liquid biopsy market statistics, including breast cancer liquid biopsy industry global market size, regional shares, competitors with a breast cancer liquid biopsy market share, detailed breast cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer liquid biopsy industry. This breast cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.78 billion in 2024 to $0.90 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. The growth during the historic period can be attributed to advancements in next-generation sequencing (NGS), the increasing prevalence of breast cancer, the growing demand for non-invasive diagnostic methods, the rising adoption of personalized medicine, and increased funding for cancer research.

The breast cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The projected growth in the forecast period is driven by technological advancements in liquid biopsy assays, increasing adoption of liquid biopsy for early cancer screening, rising demand for real-time cancer monitoring, expanding applications in precision oncology, and growing investments in liquid biopsy research and development. Key trends include the integration of artificial intelligence in liquid biopsy analysis, advancements in single-cell sequencing, the development of multi-omics liquid biopsy platforms, improvements in liquid biopsy sensitivity and specificity, and the adoption of digital PCR for ultra-precise mutation detection.

The rising number of breast cancer cases is expected to drive the growth of the breast cancer liquid biopsy market in the coming years. Breast cancer is a malignancy that originates in the breast cells, typically in the milk-producing lobules or the ducts that transport milk to the nipple. The increasing prevalence of breast cancer is attributed to factors such as genetic predisposition, hormonal imbalances, an aging population, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy plays a crucial role in treatment by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. It helps assess treatment response, detect therapy resistance, and identify genetic mutations for targeted therapies. For example, according to the American Cancer Society, a US-based nonprofit organization dedicated to cancer research, education, advocacy, and patient support, new breast cancer cases are projected to increase from 313,510 in 2024 to 319,750 in 2025. As a result, the growing incidence of breast cancer is fueling the expansion of the breast cancer liquid biopsy market.

Leading companies in the breast cancer liquid biopsy market are focusing on innovative developments, such as companion diagnostics, to facilitate personalized treatment by identifying patients who are most likely to benefit from specific therapies. Companion diagnostics leverage liquid biopsy technology to detect biomarkers, including genetic mutations, circulating tumor DNA (ctDNA), and protein expressions that indicate treatment responsiveness. For instance, in January 2023, Guardant Health Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a therapy for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to conduct comprehensive genomic profiling using the test, enabling them to identify patients who may benefit from targeted therapy. It also marks Guardant Health's first FDA approval for breast cancer, strengthening its presence in precision oncology.

In January 2024, Guardant Health Inc. partnered with Hikma Pharmaceuticals plc to enhance early cancer detection, monitor recurrence, and optimize treatment selection using Guardant Health's advanced liquid and tissue biopsy technologies. This collaboration strengthens Guardant Health's global presence and addresses the increasing cancer burden in the Middle East and North Africa. Hikma Pharmaceuticals plc is a UK-based pharmaceutical company specializing in innovative healthcare solutions.

Major players in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc.

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast cancer liquid biopsy market consists of revenues earned by entities by providing services such as early cancer detection, treatment monitoring, minimal residual disease (MRD) detection, recurrence prediction, and genetic mutation analysis for targeted therapy selection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer liquid biopsy market also includes sales of circulating tumor DNA (ctDNA) assay kits, circulating tumor cell (CTC) detection systems, next-generation sequencing (NGS) panels, PCR-based liquid biopsy tests, blood collection tubes, and consumables and reagents used for non-invasive cancer diagnostics and monitoring. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Consumables; Kits
  • 2) By Biomarkers: Extracellular Vesicles (EVs); Cell-free DNA (cfDNA); Circulating Tumor RNA (ctRNA); Circulating Tumor Cells (CTCs); Cell-free RNA (cfRNA); Other Biomarkers
  • 3) By Application: Early Detection Or Screening; Diagnosis; Other Applications
  • 4) By End Users: Laboratories; Hospitals; Physician Laboratories; Reference Laboratories; Public Health Laboratories; Research Institutes; Small Molecular Laboratories; Pathology Laboratories
  • Subsegments:
  • 1) By Consumables: Reagents; Polymerase Chain Reaction (PCR) Assays; Sequencing Panels; Sample Collection Tubes
  • 2) By Kits: DNA-based Liquid Biopsy Kits; RNA-based Liquid Biopsy Kits; Multi-marker Liquid Biopsy Kits
  • Companies Mentioned: Johnson & Johnson Private Limited; Roche Diagnostics; Merck KGaA; Thermo Fisher Scientific; Siemens Healthineers
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Liquid Biopsy Market Characteristics

3. Breast Cancer Liquid Biopsy Market Trends And Strategies

4. Breast Cancer Liquid Biopsy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Breast Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Breast Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Breast Cancer Liquid Biopsy Market Growth Rate Analysis
  • 5.4. Global Breast Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Breast Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Breast Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Breast Cancer Liquid Biopsy Market Segmentation

  • 6.1. Global Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Consumables
  • Kits
  • 6.2. Global Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Extracellular Vesicles (EVs)
  • Cell-free DNA (cfDNA)
  • Circulating Tumor RNA (ctRNA)
  • Circulating Tumor Cells (CTCs)
  • Cell-free RNA (cfRNA)
  • Other Biomarkers
  • 6.3. Global Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Early Detection Or Screening
  • Diagnosis
  • Other Applications
  • 6.4. Global Breast Cancer Liquid Biopsy Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratories
  • Hospitals
  • Physician Laboratories
  • Reference Laboratories
  • Public Health Laboratories
  • Research Institutes
  • Small Molecular Laboratories
  • Pathology Laboratories
  • 6.5. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reagents
  • Polymerase Chain Reaction (PCR) Assays
  • Sequencing Panels
  • Sample Collection Tubes
  • 6.6. Global Breast Cancer Liquid Biopsy Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • DNA-based Liquid Biopsy Kits
  • RNA-based Liquid Biopsy Kits
  • Multi-marker Liquid Biopsy Kits

7. Breast Cancer Liquid Biopsy Market Regional And Country Analysis

  • 7.1. Global Breast Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Breast Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 8.1. Asia-Pacific Breast Cancer Liquid Biopsy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Liquid Biopsy Market

  • 9.1. China Breast Cancer Liquid Biopsy Market Overview
  • 9.2. China Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Liquid Biopsy Market

  • 10.1. India Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Liquid Biopsy Market

  • 11.1. Japan Breast Cancer Liquid Biopsy Market Overview
  • 11.2. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Liquid Biopsy Market

  • 12.1. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Liquid Biopsy Market

  • 13.1. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Liquid Biopsy Market

  • 14.1. South Korea Breast Cancer Liquid Biopsy Market Overview
  • 14.2. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Liquid Biopsy Market

  • 15.1. Western Europe Breast Cancer Liquid Biopsy Market Overview
  • 15.2. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Liquid Biopsy Market

  • 16.1. UK Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Liquid Biopsy Market

  • 17.1. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Liquid Biopsy Market

  • 18.1. France Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Liquid Biopsy Market

  • 19.1. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Liquid Biopsy Market

  • 20.1. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Liquid Biopsy Market

  • 21.1. Eastern Europe Breast Cancer Liquid Biopsy Market Overview
  • 21.2. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Liquid Biopsy Market

  • 22.1. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Liquid Biopsy Market

  • 23.1. North America Breast Cancer Liquid Biopsy Market Overview
  • 23.2. North America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Liquid Biopsy Market

  • 24.1. USA Breast Cancer Liquid Biopsy Market Overview
  • 24.2. USA Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Liquid Biopsy Market

  • 25.1. Canada Breast Cancer Liquid Biopsy Market Overview
  • 25.2. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Liquid Biopsy Market

  • 26.1. South America Breast Cancer Liquid Biopsy Market Overview
  • 26.2. South America Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Liquid Biopsy Market

  • 27.1. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Liquid Biopsy Market

  • 28.1. Middle East Breast Cancer Liquid Biopsy Market Overview
  • 28.2. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Liquid Biopsy Market

  • 29.1. Africa Breast Cancer Liquid Biopsy Market Overview
  • 29.2. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Biomarkers, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Breast Cancer Liquid Biopsy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

  • 30.1. Breast Cancer Liquid Biopsy Market Competitive Landscape
  • 30.2. Breast Cancer Liquid Biopsy Market Company Profiles
    • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Roche Diagnostics Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Liquid Biopsy Market Other Major And Innovative Companies

  • 31.1. Agilent Technologies Inc.
  • 31.2. Illumina Inc.
  • 31.3. Sysmex Corporation
  • 31.4. Qiagen N.V.
  • 31.5. Myriad Genetics Inc.
  • 31.6. NeoGenomics Laboratories
  • 31.7. Guardant Health Inc.
  • 31.8. Twist Bioscience
  • 31.9. Foundation Medicine Inc.
  • 31.10. Biodesix Inc.
  • 31.11. Menarini Silicon Biosystems
  • 31.12. Datar Cancer Genetics
  • 31.13. Abcam plc
  • 31.14. OncoDNA SA
  • 31.15. Genomic Health Inc.

32. Global Breast Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Liquid Biopsy Market

34. Recent Developments In The Breast Cancer Liquid Biopsy Market

35. Breast Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

  • 35.1 Breast Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Breast Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Breast Cancer Liquid Biopsy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer